West Pharma's Beat-and-Raise: Cyber Recovery and HVP Momentum
Strong Q2 with non-GLP-1 HVP surging; leadership transition on deck
WST · Earnings Call · 2026-07-23
A Resilient Quarter That Exceeded Expectations
West Pharmaceutical Services delivered a robust Q2 2026, beating on both top and bottom lines. Revenues hit $872 million, up 12.7% organically, and adjusted EPS of $2.37 rose 29% year-over-year. Management raised full-year guidance to 10–11% organic growth and $8.85–$9.05 EPS. What made this quarter stand out was the recovery from the May cyber incident. As CEO Eric Green noted, “Our performance was driven by the execution of our strategy and continued operational excellence initiatives. This is a testament to the exceptional efforts of our colleagues whose collective actions following the cyber incident drove the recovery and these strong financial results.” — Eric Green, Chief Executive Officer, Chair of the Board · 2026-07-23 That resilience is reflected in the cyber incident keyword, which spiked to rank #2 in the company's keyword trajectory with a momentum of 207—a clear signal that this was a defining event of the quarter. CFO Bob McMahon added, “We now anticipate total HVP Components business to grow high teens organically for the year,” — Robert McMahon, Chief Financial Officer · 2026-07-23 up from the prior 7–9% guidance. The HVP Components unit, now 49% of total revenue, grew 18.4% organically, driven by non-GLP-1 strength.Non-GLP-1 HVP: The Real Surprise
The standout was non-GLP-1 HVP Components, which grew high teens and exceeded expectations. Eric attributed this to “three areas: specifically in our Biologics and Biosimilar space... the second exciting area also is really around that Annex 1 and other HVP-related upgrades... the third one is really around operational excellence.” — Eric Green, Chief Executive Officer, Chair of the Board · 2026-07-23 He cited non-GLP-1 momentum and noted that “just shy of 800 total projects in hand and that's up 50% from the same time period last year” — Eric Green, Chief Executive Officer, Chair of the Board · 2026-07-23—an acceleration of the Annex 1 pipeline. This is a continuation of a trend. On the April 2026 call, Eric had said, “We believe for the balance of the year, we'll have very strong double digits in that area,” — Eric Green, President, CEO and Chairman · 2026-04-23 referring to non-GLP-1 HVP. The Q2 result confirmed that optimism. Similarly, in February, Bob had provided historical context: “GLP-1s for the full year grew in the range of 50%.” — Robert McMahon, Chief Financial Officer (CFO) · 2026-02-12 The current quarter's high-teens growth for both GLP-1 and non-GLP-1 HVP signals normalization to a durable, balanced growth algorithm.Margin Expansion and Leadership Transition
Gross margin expanded 200 basis points to 37.7%, and adjusted operating margin rose 230 bps to 22.6%. This reflects the positive mix shift toward HVP components. Operating income grew 63% YoY on 21% revenue growth, showcasing high incremental margins. The company's focus on operational excellence and capacity utilization is paying off. Beyond the numbers, a leadership transition looms. Eric Green, the long-time CEO, will step down on August 31, with Michel Lagarde taking over. Green summarized,The stock has responded positively, up 37.6% in the last 90 days, though still 3.5% below its July peak.We have a durable business with a strong competitive moat, which delivers unique value to our customers. We're well positioned to capitalize on long-term macro trends, and we remain focused on our 3 key growth drivers of Biologics, GLP-1s and Annex 1 and other HVP conversions while leveraging our global scale.